Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Clinical Research Organizations-CROs -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (20)	12/28/1999 4:57:00 PM
From: RWReeves	Read Replies (2) \| Respond to of 46

CRO Year End wrap up. Since I'm wrapping up performance for the LTAB Small Wonders portfolio, thought it would be good to touch on CROs as well. Overall, performance of the unmanaged CRO basket has been up 8.4% since portfolio inception of 11/19/99 (let's say 40 days). siliconinvestor.com Looking at individual stocks has been more profitable. As I mentioned, I like KNDL especially and it has been up well. QTRN has been very disappointing, it's the NYSE capitalization brute of the bunch. I did sell of my QTRN holdings (which I consider very long term) to chase genomics momentum and that's been a decision without regret. Come January, I'm re-establishing positions in QTRN and adding a few others. CRSC had a nice a nice run. A rare opportunity to do a day trading in a CRO. I will also be adding RX to the portfolio, which for those of you in the industry will recognize as IMS data- THE source of data for drugs, diagnostics, etc sales. It really is the data gorilla, although not technically a CRO does provide data to pharma/bios. Think its a fit, please read the 10K its is very informative as to how this works. Been too busy churning...ah.. trading the portfolio to post much, hope to do more next year, perhaps adjust the portfolio for the relative prospects. I may add ILXO, which also provides specialized clinical trial services in the cancer area as well as doing it's own product development. Look for improvements in the sector as investors realize increasing regulation and price pressure mean more trials and more pharmaco-economics. Best Holiday wishes to all... RWR

To: RWReeves who wrote (20)	1/24/2000 6:26:00 PM
From: RWReeves	Read Replies (1) \| Respond to of 46

QTRN breaks out today with a bid for the mid 30's only to fall back to 27 in general market ugliness. What me worry? Nevertheless, <QTRN, another chance at the 18-19 price. Patience with this one.> was posted 12/23 and it is up nearly 100% if you sold off on the spike as I did. ...And bought KNDL, which I think has lots better leverage than QTRN and some CVD. If the CRO's have now come to the attention of The Street as "tools" companies, not relying on FDA approval to sell, but on R&D bucks to be spent, I'd say the writing on the wall is pretty clear, eh? This sector may never get the sex appeal of genomics ( well PPDI might, VTIV is pure uncut corporate pharma and CVGR, well, read the filings for an interesting saga. But actually these pups have some (IMO) better near term earnings outlook. When momo abandons you and your broker calls about those nasty margin requirements in the handbook, these are worth remembering. QTRN calls this morning were not too expensive either. RWR